Search
Medicaid Monitor
Saturday, November 21, 2026 · Updated Fri 12:06 PM MT · 52 stories on Friday, November 20
Medicaid Monitor Pro
Sat, Nov 21 · 52 stories on Friday, November 20PRO
Section

Federal Policy

6 stories on Friday, November 20 · Page 4 of 44

Latest

  1. Federal Policy

    Sen. Kim's MediKids Bill Gains Traction in House Democrats' Agenda

    Becker's Hospital Review reports that as Medicare for All drew strong polling support ahead of the 2026 midterms, House Democrats' healthcare agenda stopped short of endorsing it, instead citing a consensus push toward universal coverage with Sen. Andy Kim's "MediKids" bill gaining traction. The bill, introduced in July, would broaden Medicaid eligibility to guarantee coverage through age 26, require states to automatically enroll newborns, allow guardians to opt out if other coverage exists, and set coverage without regard to immigration status. It would set the federal medical assistance percentage at 100% for the newly eligible population, with most provisions taking effect two years after enactment. The American Academy of Pediatrics and American College of Obstetricians & Gynecologists have endorsed the bill, and a New York Times commentary noted it was designed with budget reconciliation in mind.

    Becker's · 11 days ago
  2. Federal Policy

    FDA Mandates Vision Loss Warning on GLP-1 Drug Labels

    The FDA issued a Nov. 9 drug safety communication requiring labeling changes for GLP-1 receptor agonists, including Eli Lilly's Mounjaro and Zepbound and Novo Nordisk's Ozempic and Wegovy, to add warnings about non-arteritic anterior ischemic optic neuropathy (NAION), a rare condition that can cause sudden, permanent vision loss in one eye. The FDA said it based the decision on clinical trial, animal and postmarket data, including observational studies and case reports. Novo Nordisk had already added a similar warning to European labels in June, but the warning had been absent from U.S. labels, and the American Academy of Ophthalmology previously said evidence did not support a blanket U.S. warning. The action comes as at least 4,000 consolidated claims allege GLP-1 drugs caused vision loss, and both drugmakers dispute a causal link.

    Becker's · 12 days ago
  3. Federal Policy

    CMS Requests Comment on Part D Pharmacy Contract Standards

    CMS published a Sept. 24 Federal Register request for information asking what should count as "reasonable and relevant" terms in contracts between Medicare Part D plan sponsors and network pharmacies, a phrase CMS has never defined despite requiring it under existing rules. The request is a first step toward implementing a Consolidated Appropriations Act of 2026 provision requiring any willing pharmacy to participate in Part D networks starting with plan years on or after Jan. 1, 2029. CMS is seeking input on reimbursement and dispensing fees, specialty pharmacy designation, 340B contract terms, contract transparency, and quality/audit practices. Comments are due Nov. 23 under Docket CMS-2026-3037, a deadline the SBA's Office of Advocacy flagged to small businesses on Nov. 9.

    Becker's · 12 days ago
  4. Federal Policy

    CMS Delays Medicare Third-Party RPM Payment Ban to 2029

    CMS finalized a two-year delay, to January 1, 2029, of a proposal ending Medicare payment for remote patient monitoring services provided by third-party vendors contracting with healthcare providers, according to Healthcare Dive. The original start date was January 1, 2027. CMS cited HHS Office of Inspector General findings that third-party contracting has led to fraud and improper billing, since billing providers may lack oversight of care delivered by outside vendors. Under the finalized policy, Medicare will eventually pay only for RPM services provided by clinical staff employed by the practice treating the patient. CMS also finalized a separate change limiting payment for monitoring of non-physiologic metrics, such as medication adherence and pain levels, to established patients. Virtual care lobbying groups including ATA Action and the Connected Health Initiative said they will use the two-year window to push CMS for program-integrity safeguards that preserve RPM access.

    Healthcare Dive · 12 days ago
  5. Federal Policy

    FDA Investigates Cancer Risk in Novartis's Zolgensma Gene Therapy

    The FDA is investigating postmarket reports of malignancies, including confirmed cases of product-related insertional oncogenesis, in patients treated with Novartis's gene therapy Zolgensma for spinal muscular atrophy, according to a Nov. 6 agency safety communication. Reports include tumors of the central and peripheral nervous systems, spinal and paraspinal regions, and kidney; three cases involved the GLI1 oncogene, and in two the therapy's viral vector DNA had integrated near or within that gene. The FDA determined the risk applies to both onasemnogene abeparvovec products, Zolgensma (IV infusion for children under 2) and Itvisma (intrathecal injection for patients 2 and older), since they share the same vector and construct, though no neoplasia cases have been reported after Itvisma. The agency said overall benefits still outweigh risks for approved uses but is evaluating whether the product label and Novartis's long-term follow-up studies are adequate.

    Becker's · 12 days ago
  6. Federal Policy

    GAO Finds Broad Medicare, Medicaid Coverage of Overdose Reversal Drugs

    GAO reports that all Medicare Part D and Medicaid enrollees had coverage of some form of naloxone in 2025 and 2024, respectively, while coverage of nalmefene, a newer and longer-acting overdose reversal medication, was less common. Part D out-of-pocket costs ranged from $3 to $10 median copays for generic naloxone injections up to 25 to 35 percent coinsurance for brand high-dose naloxone and nalmefene nasal sprays. Among four selected state Medicaid programs GAO reviewed, two had no copays and two had copays under $5. GAO analyzed 2025 Part D data and 2024 Medicaid drug reimbursement data from all 50 states and DC, and interviewed four plan sponsors and four state Medicaid programs about coverage and cost factors.

    GAO · 12 days ago
  7. Federal Policy

    CMS Awards $10 Billion in Year Two Rural Health Transformation Funding

    CMS announced $10 billion in second-year awards to all 50 states under the Rural Health Transformation Program, part of a five-year, $50 billion initiative created by the Working Families Tax Cuts Act. State FY2027 awards range from roughly $142 million to $282 million and were determined partly on states' progress implementing their approved transformation plans, including state policies such as the Presidential Fitness Test and physician continuing education on nutrition. States will use the funds to advance initiatives in their approved plans, including chronic disease prevention, workforce development, care and payment model innovation, and technology for rural providers. The program's five-year structure is intended to let states build, test, and scale approaches over time.

    CMS · 12 days ago
  8. Federal Policy

    Georgetown CCF: Child SNAP Losses Outpace Medicaid/CHIP Enrollment Drops

    Georgetown University's Center for Children and Families reports that child enrollment in Medicaid and CHIP fell by 2.56 million nationally from January 2025 through August 2026, based on state administrative data and CMS reporting. Drawing on Center on Budget and Policy Priorities tracking across 26 states, CCF finds child SNAP enrollment fell 15.7% (about 1.6 million children) from January 2025 to May 2026, compared to a 6.3% drop in Medicaid/CHIP enrollment in those same states, with the gap widening after H.R. 1's enactment in July 2025. CCF attributes the SNAP decline largely to H.R. 1 provisions already in effect, including tightened work reporting requirements and cuts to federal administrative funding, while noting Medicaid/CHIP's 12-month continuous eligibility requirement may be slowing similar losses there. CCF states children make up about 42% of those losing SNAP since July 2025 in tracked states.

    Georgetown CCF · 12 days ago
  9. Federal Policy

    KFF Experts: Election Results Raise Pressure to Reverse Medicaid Cuts

    In a KFF webinar reported by Kansas Reflector, health policy experts discussed how Tuesday's Democratic election wins could shape healthcare policy. KFF's Larry Levitt said Democrats face high expectations to reverse Medicaid cuts from the One Big Beautiful Bill Act and restore ACA premium subsidies, but face a likely Trump veto and limited time before the 2028 election cycle slows Congress. Washington health policy reporter Amanda Seitz said Republicans view the Medicaid cuts as a signature achievement and doubted Trump would reverse them, but said rulemaking on Medicaid, including a court challenge to the definition of Medicaid frailty and work requirements set to take effect January 1, should be watched closely. KFF Health News' Julie Rovner noted Democrats have released an 84-page healthcare policy paper but questioned how they would pay for reversing roughly a trillion dollars in Medicaid cuts and hundreds of billions in ACA subsidy costs.

    kansasreflector.com · 12 days ago
  10. Federal Policy · VT

    Sanders Vows to Reverse Medicaid Cuts as Likely HELP Chair

    Sen. Bernie Sanders, I-Vt., said he intends to reclaim the chairmanship of the Senate Health, Education, Labor and Pensions Committee after Tuesday's election put Democrats in control of both chambers of Congress. In an interview, Sanders said he would use the post to try to rescind provisions of the One Big Beautiful Bill Act that are slated to push millions of people off Medicaid, and to restore enhanced Affordable Care Act subsidies that lapsed last year. He also said he wants the committee to "be very aggressive about moving toward 'Medicare for All'," remarks he made Thursday. Democrats were projected as of Friday to control at least 54 Senate seats and 253 House seats, with some races still uncalled.

    vtdigger.org · 12 days ago
  11. Federal Policy

    Democrats begin asking: How far can we go on health care?

    STAT News · STAT+ subscriber · 12 days ago
  12. Federal Policy

    SHVS Analyzes CMS, IRS Proposed Rules on ACA Verification Rules

    In a resource analyzing two federal proposed rules, State Health and Value Strategies (SHVS) reports that the IRS released a proposed rule on October 15 and CMS released a proposed rule on October 27 to implement premium tax credit and eligibility verification changes required by the 2025 budget reconciliation law (H.R. 1). SHVS states the CMS rule would end automatic re-enrollment for subsidized Marketplace consumers, require manual re-enrollment each year, and deny subsidies while eligibility is being verified, creating months-long waits for some consumers. The analysis says these changes would impose substantial new administrative burdens on State-Based Marketplaces, which would need to rebuild eligibility and enrollment systems, and notes the new requirements have an August 1, 2027 go-live date that SHVS says the rule is unlikely to be finalized in time to meet. SHVS also notes mitigation provisions, including an extended verification period, pended enrollment, and retroactive financial assistance, but says these may be complex or unworkable.

    shvs.org · 15 days ago
  13. Federal Policy

    Democrats’ midterm landslide spells relief for hospitals

    STAT News · STAT+ subscriber · 15 days ago
  14. Federal Policy

    KFF Finds Medicaid Rate Transparency Rules Cover Narrow Service Slice

    In a new brief, KFF describes Medicaid fee-for-service payment transparency requirements that took effect in July 2026 under the Ensuring Access to Medicaid Services final rule, including comparative rate analyses against Medicare, published fee schedules, and disclosure of home care hourly rates. Using T-MSIS data, KFF finds that the 68 billing codes CMS specified for the Medicaid-to-Medicare comparative rate analysis account for only 2% of noninstitutional FFS spending and 5% of noninstitutional FFS claims. KFF notes that comparing rates across states remains difficult due to variation in reporting practices, populations, and geographic areas, and that the value of the comparative data will depend on each state's delivery system and how closely MCO rates track FFS rates. Separate managed care payment transparency requirements apply to rating periods beginning on or after July 9, 2026, with analyses due in Network Adequacy and Access Assurances Reports submitted starting January 1, 2028.

    KFF Research · 15 days ago
  15. Federal Policy

    CMS Finalizes 2.4% Medicare Home Health Pay Hike, Tighter Enrollment Rules

    CMS finalized its calendar year 2027 home health payment rule, projecting a 2.4% aggregate payment increase, or about $415 million, combining a 2.1% payment update and an estimated 0.3% fixed dollar loss adjustment. The rule also finalizes a 3% temporary reduction to the national standardized base payment rate to continue recouping prior overpayments tied to the payment model. CMS withdrew or narrowed some enrollment proposals but retained broader provider enrollment and disclosure provisions, including treating clinical leadership titles as presumptively reportable managing employees, with revocations that can apply retroactively to when noncompliance began. Home health leaders told Home Health Care News the rate increase is welcome but does not fully offset recruitment and compliance costs, particularly for providers in rural areas.

    Home Health Care News · 15 days ago
  16. Federal Policy

    CMS Finalizes Permanent Rules for Medicare Drug Price Negotiation

    CMS finalized a rule establishing a permanent framework for the Medicare Drug Price Negotiation Program, with policies taking effect for prices beginning in 2029. By Feb. 1, 2027, CMS will select up to 20 additional negotiation-eligible drugs for the program's fourth cycle, along with drugs for renegotiation. The rule addresses fixed combination drugs CMS deems new formulations of existing drugs to prevent circumvention of maximum fair prices, implements a required temporary price floor for small biotech drugs for 2029-2030, and codifies Part D requirements that plans include selected drugs with an effective maximum fair price on their formularies and cap prices paid to dispensing entities at that price plus dispensing fees.

    CMS · 15 days ago
  17. Federal Policy

    CMS Proposes Rolling Back Medicare, Medicaid Facility Requirements

    On Nov. 5, 2026, CMS issued the CARE proposed rule revising Conditions of Participation and related requirements for Medicare- and Medicaid-participating providers across 21 provider and supplier types. The rule would remove staff training requirements for OB care, emergency readiness, and transfer protocols at hospitals and critical access hospitals; streamline COVID-19 vaccine and reporting requirements at long-term care facilities, ICFs/IID, and rural emergency hospitals; update physical environment and fire safety codes; and add new patient-rights requirements for birth tissue collection by hospitals and CAHs offering OB care. It also proposes rescinding Medicaid institutional payment transparency reporting requirements that track the share of nursing facility and ICF/IID payments spent on direct care worker and support staff compensation. CMS estimates the proposals would save $320 million and return more than 3.26 million staff hours, and the rule includes comment solicitations for stakeholder input.

    CMS · 15 days ago
  18. Federal Policy

    Sanders calls for Democrats to pass 'Medicare for All'

    The Hill · 16 days ago
  19. Federal Policy

    CMS Proposes Rule on Part D Cost-Sharing, PBM Accountability

    In a client alert, King & Spalding reports that CMS published a proposed rule on October 20, 2026 to implement three sections of the Consolidated Appropriations Act of 2026. The sections cover adjustments to Medicare Part D cost-sharing reductions for low-income individuals, requirements for enhanced and accurate provider directories, and pharmacy benefit manager accountability measures. The rule would amend existing Medicare Advantage, Part D, and PBM regulations.

    jdsupra.com · 16 days ago
  20. Federal Policy

    USCIS Guidance on Public Charge Rule Omits Key Definitions

    In an issue brief, KFF reports that USCIS issued Policy Manual guidance on August 18, 2026 to implement DHS's July 2026 final rule, which rescinded 2022 Biden-era public charge regulations and took effect September 18, 2026. The new rule removed prior definitions of "public charge" and the determination framework without replacing them, and the guidance likewise does not define who may be considered a public charge or provide an exhaustive list of benefits counted in determinations, leaving officers broad discretion. KFF states this applies to USCIS adjustment of status adjudications only, not determinations made by Customs and Border Protection, the State Department, or immigration courts. KFF notes the lack of detail will likely increase confusion and fear among immigrant families, potentially limiting participation in public programs including among citizen children in these families.

    KFF Research · 16 days ago

Get the daily briefing.